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Abstract
Disruption of the regulatory mechanisms that control cell proliferation and cell migration 
results in multiple disease states including cancer and leukaemia. The proline-rich home-
odomain protein (PRH)/haematopoietically expressed homeobox protein (HHEX) is a tran-
scription factor that controls cell proliferation and cell migration in a variety of tissues in the 
adult and in the embryo. Phosphorylation of PRH by Protein Kinase CK2 (Casein Kinase II) 
stops PRH from binding to DNA and regulating the transcription of its direct target genes. In 
leukaemic cells, phosphorylation also results in the production of a transdominant-negative 
truncated PRH phosphoprotein by the proteasome. Phosphorylation of PRH is increased in 
breast and prostate cancer cells and the consequent loss of PRH activity increases cell prolif-
eration and migration. PRH also regulates the proliferation of vascular smooth muscle cells 
and CK2-dependent phosphorylation of PRH in these cells accompanies increased cell prolif-
eration during intimal thickening. Thus the ability of PRH to regulate cell behaviour and the 
control of PRH by CK2 is not limited to a specific cell type or tissue. This raises the possibility 
that the PRH-CK2 axis could be targeted in a variety of disease states ranging from multiple 
cancers to the intimal thickening that occurs in vein bypass graft failure and restenosis.
Keywords: cell proliferation, cell migration, cell invasion, tumourigenesis, tumour 
growth, restenosis, intimal thickening
1. Introduction
The proline-rich homeodomain (PRH) or haematopoietically expressed homeobox (HHEX) 
protein, is a highly conserved transcription factor belonging to the homeodomain family 
(reviewed by Soufi et al. [1]). Originally characterised in the haematopoietic compartment 
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[2–4], PRH has since been found in a wide variety of tissues [1]. PRH is critically important in 
embryonic development where it regulates anteroposterior axis formation and the develop-
ment of multiple organ systems including the liver, thyroid, lung, thymus, gallbladder and 
pancreas [5–8]. In the adult, PRH is expressed in a variety of tissues including the thyroid, 
lungs, liver and haematopoietic compartment [4, 9]. In these tissues PRH acts as a master 
regulator of genes important in cell proliferation, cell migration and invasion, and cell differ-
entiation [1]. Changes in PRH activity therefore have profound effects on cell behaviour. This 
review focuses on the regulation of PRH activity by Protein Kinase CK2 and the role that this 
plays in tumourigenesis and in the control of vascular smooth muscle cell (VSMC) prolifera-
tion during intimal thickening.
2. The regulation of gene expression by PRH
2.1. The PRH protein
The PRH protein has three functional domains; a central homeodomain that mediates DNA 
binding, with N-terminal and C-terminal domains that regulate transcription (Figure 1). 
The PRH homeodomain is a 60 amino acid sequence that forms three α helices. The sec-
ond and third helices make up a helix-turn-helix motif and together with amino acids in an 
N-terminal arm of this domain, this mediates sequence-specific DNA binding. The muta-
tion of asparagine to alanine at position 187 within the PRH homeodomain dramatically 
reduces DNA binding and prevents PRH from repressing the transcription of its direct target 
genes [10, 11]. The PRH homeodomain also mediates binding to transcription factor AP1 
[12]. The PRH N-terminal domain can repress transcription when attached to a heterologous 
DNA binding domain [10, 13]. Additionally, the N-terminal domain interacts with a variety 
of proteins including the promyelocytic leukaemic (PML) protein, eukaryotic initiation fac-
tor 4E (eIF-4E), proteasome subunit C8, and the regulatory subunit of Protein Kinase CK2 
Figure 1. PRH and PRH-interacting proteins. A schematic representation of the PRH protein. The homeodomain and the 
N- and C-terminal domains are indicated along with the serine residues known to be phosphorylated by CK2 (S163 and 
S177). PRH-interacting proteins are listed and their binding sites on PRH are indicated by brackets. Some of the protein-
protein interactions have not been mapped to defined regions of PRH.
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[14–17]. The C-terminal domain is rich in acidic residues and it also functions in transcrip-
tional regulation since its loss prevents PRH from activating transcription of the sodium-
dependent bile acid co-transporter (NTCP) gene [18, 19].
The PRH protein forms oligomeric complexes in vitro and in cells [20]. The PRH N-terminal 
domain is resistant to SDS (sodium dodecyl sulphate)-induced denaturation and does not 
have extensive α-helical or β-sheet secondary structures. However, this domain forms dimers 
that interact with the PRH homeodomain [20]. In vitro studies suggest that octameric PRH 
oligomers form via the association four PRH dimers [20]. This has implications for DNA bind-
ing since although the isolated PRH homeodomain binds to a single DNA site, the full length 
PRH protein binds to linear arrays of homeodomain binding sites with high affinity [21]. 
Several genes that are directly regulated by PRH including Goosecoid (GSC), TLE4, VEGFA, 
VEGFR-1 (FLT1), and endothelial cell-specific molecule-1 (ESM-1) contain multiple, putative 
PRH-binding sequences [8, 21–23]. This suggests that PRH oligomers bind to these linear 
arrays to regulate gene expression. However, it is possible that a single PRH binding site may 
be sufficient to confer gene regulation by PRH.
2.2. The regulation of gene expression
Like many transcription factors PRH can either repress or activate transcription depending 
on its target gene (see Soufi et al. [1] and Gaston et al. [40] for lists of PRH target genes) and 
its partner proteins (shown in Figure 1). For example, PRH represses the Goosecoid, ESM-
1, VEGFA, VEGFR-1, VEGFR-2, and thyroglobulin promoters [8, 21, 23, 24]. An Eh1 motif 
in PRH N-terminal domain allows PRH to recruit members the Groucho/transducin-like 
enhancer of split (TLE) family of co-repressor proteins which in turn recruit histone deacety-
lases [25]. Similarly, PRH can repress transcription by recruiting the polycomb-repressive 
complex 2 (PRC2) to target genes to bring about histone methylation [26]. These co-repressor 
interactions can bring about short- and long-range transcriptional repression through histone 
modification and consequent chromatin condensation. PRH can also repress transcription by 
interfering with other transcription factors. Binding of PRH to GATA-2 suppresses GATA-2-
mediated activation of vascular endothelial growth factor receptor 2 (VEGFR-2) transcription 
[27]. Similarly, PRH binds to Jun and cMyc inhibiting Jun- and cMyc-dependent transcription 
activation, respectively [12, 28]. PRH also activates transcription through multiple mecha-
nisms including direct binding to target promoters as in the case of the NTCP promoter [19]. 
Moreover, PRH binding to hepatocyte nuclear factor 1α (HNF-1α) and serum-response factor 
(SRF) increases HNF-1α- and SRF-activated transcription [29, 30]. In addition, PRH can regu-
late gene expression post-transcriptionally through binding to eIF-4E. PRH binding to eIF-4E 
in PML nuclear bodies disrupts these structures and blocks eIF-4E-dependent transport of 
cyclin D1 mRNA down-regulating cyclin D1 protein expression [15].
2.3. PRH activity in tumourigenesis
Inappropriate expression and/or aberrant subcellular localization of PRH has been observed 
in a variety of disease states including acute myelogenous leukaemia (AML) [31, 32], chronic 
myelogenous leukaemia (CML) [32], breast, thyroid, and prostate cancer [33–36], liver disease, 
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and cardiovascular disease [37, 38]. In normal haematopoietic cells PRH protein is clearly dis-
cernable in distinct foci within the nucleus, co-localising with PML and translation factor eIF-
4E [14, 25], whereas in AML and CML PRH appears to be mislocalised to the cytoplasm [32]. 
Comparably, in thyroid cancer and breast cancer cells, PRH appears to be mislocalised from 
the nuclear compartment to the cytoplasm and often shows down-regulation in expression 
[33–35]. In breast and prostate cells loss of PRH activity results in increase cell proliferation 
and increased cell migration and invasion [35, 36]. Moreover, PRH over-expression in mouse 
mammary tumour cells inhibits tumour growth in vivo [36]. Similarly, PRH over-expression 
in liver cancer cells inhibits tumour growth in a xenograft mouse model [39] and PRH directly 
interacts with c-Myc to inhibit hepatocyte proliferation [28]. These studies are consistent with 
PRH playing a tumour suppressive role in these cell types.
In contrast, PRH has been shown to function as an oncoprotein in T-cell lineages and in AML 
subtypes (reviewed by Gaston et al. [40]). In retroviral insertion experiments in mice (Lvis1)-
elevated PRH expression is associated with B-cell- and T-cell-derived leukaemias and lym-
phomas [41, 42]. Transgenic mice with ectopic PRH expression in T cell progenitors showed 
increased numbers of progenitors but this did not result in leukaemia [43]. However mice 
transplanted with bone marrow cells transduced with a retrovirus expressing PRH exhibit 
aggressive neoplastic transformation within T-cell populations [44] and in mouse models of 
early T-cell precursor-like acute lymphoblastic leukaemia (ETP-ALL), PRH is important in 
Lmo2-driven T-cell self-renewal [45, 46]. Furthermore, in a mouse model of AML elevated 
PRH is essential for the initiation and maintenance of the leukaemia [26]. Interestingly a 
human AML has been identified where alteration of the Nup98 and PRH genes to form a 
fusion gene is the only identified cytogenetic abnormality [31].
2.4. PRH in vascular compartments
PRH is expressed in the developing vascular system in haematopoietic and endothelial pro-
genitor cells [9]. PRH over-expression inhibits haematopoietic and vascular development in 
embryoid bodies [47] while PRH loss leads to abnormal vasculogenesis and cardiac morpho-
genesis [5]. PRH can inhibit the proliferation of leukaemic cells by repressing the transcription of 
VEGFA and other genes involved in VEGF signalling and haematopoietic and vascular biology 
[48]. PRH is also important in neo-angiogenesis; in endothelial cells PRH represses transcription 
of multiple genes that control blood vessel formation including VEGFR-1, VEGFR-2, tyrosine 
kinase with Ig and EGF homology domains (TIE)-1, TIE-2, and neuropilin-1 [27, 49]. PRH is also 
targeted by urokinase-type plasminogen activator (uPA). uPA regulates angiogenesis and vascu-
lar permeability by proteolytic degradation of the extracellular matrix and through intracellular 
signalling. Single chain uPA is transported from the cell surface receptors to the nucleus where 
it modulates gene transcription by binding to transcription factors including PRH. The binding 
of uPA to PRH derepresses VEGFR-1 and VEGFR-2 thereby promoting their expression [50].
Importantly, PRH is up-regulated in VSMCs after balloon injury of the rat aorta [37]. During 
the period of cell dedifferentiation and cell proliferation following injury, PRH activates 
transcription of SMemb/NMHC-B, a marker for dedifferentiated cells [37]. Moreover, over-
expression of PRH in embryonic fibroblasts results in the expression of early, but not late, 
markers of VSMC differentiation [29]. It has also been reported that in VSMCs infected 
with Human Cytomegalovirus (HCMV) PRH up-regulation promotes cell proliferation and 
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inhibits apoptosis [51]. Our recent work has shown that PRH inhibits the proliferation of 
human and rat VSMCs (see Section 6.2 [38]). This suggests that HCMV infection may switch 
PRH from being an inhibitor of VSMC proliferation to an activator.
3. Protein kinase CK2
3.1. CK2 structure
Protein Kinase CK2 (formerly known as Casein Kinase II) is a ubiquitously expressed 
enzyme important in a range of cellular functions and processes including cell cycle pro-
gression and cell migration and invasion [52]. CK2 is a Ser/Thr kinase with the minimal 
consensus target sequence Ser/Thr– X – X – Asp/Glu/pSer (where X indicates any non-
basic amino acid). However, CK2 can phosphorylate wide variety of target sequences. CK2 
exists as a hetero-tetrameric enzyme consisting of two catalytic α subunits and two regu-
latory β subunits. In humans, two isoenzymic forms of the catalytic subunit, designated 
α and α′, are well-characterised while a more recently discovered α″ subunit is less well 
understood [53–55].
3.2. CK2 function
CK2 is important in the control of cell migration and cell proliferation and in many other 
cell functions. To this end CK2 is pleiotropic, in that it has multiple effects via the phos-
phorylation of numerous cytoplasmic and nuclear proteins. For example, phosphorylation 
of inhibitor of kappa B (IκB) by CK2 causes disassembly of the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB)-IκB complex [56]. This allows NF-κB to regu-
late the transcription of genes involved in cell cycle progression and cell survival. CK2 is 
also important in the control of extracellular proteins. For example, phosphorylation of the 
extracellular matrix protein vitronectin by CK2 is important for the adhesion of VSMCs 
[57]. CK2 itself is regulated by multiple signalling cascades and can cross talk to co-ordi-
nate cell survival and cell proliferation. The ABL, Src and ERK kinase families all act as 
upstream regulators of CK2 and inhibitors that target these kinases can be used to inhibit 
CK2 indirectly [58–60].
3.3. CK2 in tumourigenesis
Aberrant CK2 activity has been demonstrated to be oncogenic and elevated CK2 expression is 
seen in multiple cancers including breast [61], prostate [62], lung [63], head and neck [64], and 
kidney cancers [65]. CK2-mediated abrogation of tumour suppressor activity or stimulation 
of oncogenic proteins has been demonstrated to play a significant role in tumourigenesis. The 
tumour suppressors promyelocytic leukaemia protein (PML), connexin, and phosphatase and 
tensin homology protein (PTEN) are all CK2 substrates that are inactivated by phosphoryla-
tion [66]. CK2 has additionally been shown to potentiate aberrant activation of oncoproteins 
including NF-κB [56], and AKT [67]. Drugs that inhibit CK2 have proven to be well-tolerated 
in a number of clinical trials and systemic or local delivery of these inhibitors is therefore a 
potential treatment for multiple disease states [68, 69].
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4. The regulation of PRH by CK2
4.1. CK2 binds to PRH and phosphorylates the homeodomain
To identify PRH binding proteins we performed a yeast two hybrid screen using PRH as 
bait. This showed that the regulatory β subunit of CK2 can bind to the PRH N terminal 
domain [17]. The interaction was confirmed in human chronic myeloid leukaemia K562 cells 
using pull-down experiments and co-immunoprecipitation [17]. Importantly, PRH is a phos-
phoprotein in these cells and pharmacological inhibition of CK2 with DMAT (2-dimethyl-
amino-4,5,6,7-tetrabromo-1H-benzimidazole) or TBB (4,5,6,7-tetrabromo-1H-benzotriazole) 
significantly reduces the amount of phosphorylated PRH (pPRH) indicating that PRH is also 
a CK2 substrate [17]. CK2β controls substrate specificity and therefore the interaction with 
PRH is potentially of importance for the control of CK2 activity on other specific substrates as 
well as in the phosphorylation of PRH.
To map CK2 phosphorylation sites within PRH, purified, human PRH protein was incubated 
with CK2 and ATP and subjected to surface-enhancer laser desorption/ionisation time-of-
flight mass spectrophotometry (SELDI-TOF-MS) analysis. This showed that S163 and S177 
located within the PRH homeodomain can be phosphorylated by CK2 [17]. S163 is located 
within a CK2 target consensus site while S177 is within a non-consensus site. Subsequently 
further phosphorylation sites have been identified within PRH but these sites have not been 
associated with a specific kinase.
4.2. Phosphorylation of PRH blocks DNA binding
Phosphorylation of the PRH homeodomain by CK2 abrogates PRH DNA-binding activity in 
vitro [17]. Interestingly DNA binding activity is restored by a subsequent incubation of pPRH 
with calf intestinal alkaline phosphatase. Thus, CK2-mediated phosphorylation of PRH func-
tions as a reversible switch for DNA binding [17]. CK2 has also been shown to inhibit the 
binding of PRH to DNA in cells. Ectopic over-expression of PRH in K562 cells represses tran-
scription of the PRH target gene VEGFR-1 but this repression is lost on co-transfection with 
CK2α and β transgenes [48]. However, the repression of VEGFR-1 transcription by a PRH 
mutant in which phosphorylation of serine 163 and serine 177 is prevented by the replace-
ment of these residues by cysteine residues is not inhibited by CK2 over-expression [48]. 
Quantitative chromatin immunoprecipitation (ChIP) showed that CK2 over-expression does 
not prevent the binding of PRH S163C,S177C to the VEGFR-1 promoter as it does with wild-
type PRH [48].
4.3. Phosphorylation of PRH induces protein processing
Hypo-phosphorylated PRH is stable in K562 cells treated with the translation inhibitor 
anisomycin [48]. However, pPRH is rapidly degraded in these cells. The half-life of pPRH 
is extended by treatment with proteasome inhibitors showing that phosphorylation targets 
PRH for proteasome-mediated protein cleavage. Interestingly, pPRH is cleaved to produce 
is a stable truncated protein that lacks the C-terminal domain (PRHδC). Over-expression of 
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CK2 increases the production of this cleavage product and the truncated protein can act as 
transdominant negative regulator of full-length PRH by sequestering TLE co-repressor pro-
teins and possibly other PRH interacting proteins [48]. This suggests that phosphorylation 
of PRH not only blocks DNA binding but also acts to prevent unphosphorylated PRH from 
regulating transcription (Figure 2). As might be expected, PRH S163C,S177C cannot be phos-
phorylated at these residues and this protein is not processed by the proteasome. In contrast, 
the phosphomimetic PRH S163E,S177E is more readily processed to produce PRHδC than 
wild type PRH [48].
4.4. pPRH in tumourigenesis
Pre-clinical studies have shown that pPRH is elevated in benign prostatic hyperplasias and 
in breast ductal carcinoma in situ compared to normal tissues [35, 36]. PRH localization is 
also altered in prostate and breast tumours compared to normal tissue. Both increased pPRH 
and increased PRH cytoplasmic localization are indicative of PRH inactivation and it is likely 
that this contributes to increased cell proliferation in these diseases. Interestingly, pPRH is 
less highly elevated in aggressive prostate adenocarcinomas and invasive breast carcinomas 
[35]. This could be due to decreased total PRH expression in these cancers. Thus high levels 
of pPRH appear to correlate more with hyperproliferative disease in these tissues rather than 
with advanced cancer.
5. PRH and CK2 in tumourigenesis
5.1. pPRH and PRH as potential biomarkers
The identification of protein modifications that contribute to increased cancer cell prolifera-
tion and increased cell migration and invasion is likely to result in new therapeutic approaches 
that could be of great benefit to patients. Moreover such cancer biomarkers could be useful as 
prognostic indicators and as indicators of pharmacologic responses to a therapeutic interven-
tion. Prognostic biomarkers that can flag a tumour as potentially benign or requiring further 
treatment are urgently required. Many breast and prostate tumours for example do not need 
Figure 2. Phosphorylation of PRH by CK2 induces protein cleavage. PRH recruits co-repressor proteins including TLE 
to target genes such as VEGFR-1 in order to repress transcription. Phosphorylation of PRH by CK2 (shown as a filled 
lollipop) prevents PRH from binding to DNA and targets the protein for processing by the proteasome. The PRHδC 
protein cannot bind to DNA but it can sequester TLE proteins (and possibly other PRH interacting proteins) and thereby 
block transcriptional repression by PRH.
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intervention and are currently over-treated by surgery because of a lack of biomarkers for 
prognosis. In pre-clinical studies the levels and localization of pPRH and PRH appear to be 
altered in breast and prostate tumours compared to controls [35, 36]. However, additional 
studies with large numbers of patients will be required to determine whether pPRH and PRH 
or the pPRH/PRH ratio is a good prognostic indicator.
5.2. The restoration of PRH function
Since PRH appears to be inactivated in breast and prostate cancer cells by CK2-dependent 
phosphorylation resulting in increased cell proliferation and cell migration, the inhibition of 
CK2 in these tissues would be expected to restore PRH function. This would be expected to 
inhibit cell proliferation and it could inhibit tumour growth. CK2 inhibitors have been pro-
posed as novel treatments for multiple cancers including prostate cancer. In normal immor-
talised prostate epithelial cells the inhibition of proliferation brought about by the inhibition 
of CK2 requires the presence of PRH [35]. It is likely that CK2 inhibitors will have similar 
effects in other cancer cell types through the prevention of PRH phosphorylation and the 
restoration of PRH function. Indirect inhibition of CK2 activity can also restore PRH function 
and re-establish the control of cell proliferation. Our previous work showed that in chronic 
myeloid leukaemia cells Dasatinib decreases CK2 activity and decreases the phosphorylation 
of PRH [58]. Dasatinib inhibits membrane bound tyrosine kinases and Src family kinases and 
is an efficacious therapeutic for leukaemias expressing BCR-ABL fusion proteins and those 
with activated Src [70]. Importantly, Src-kinases are known to stimulate CK2 activity [59]. It 
is possible that other Abl/Src kinase inhibitors will also restore PRH activity via the indirect 
inhibition of CK2. However, since PRH can act as oncoprotein in some cell types it is possible 
that the reduction of PRH phosphorylation in these cell types might be counterproductive.
6. Saphenous vein graft failure
6.1. Intimal thickening in saphenous vein grafts
Atherosclerotic plaque development within coronary arteries is a major precursor for myo-
cardial infarction (commonly known as heart attack). Coronary artery bypass graft (CABG) 
surgery is an effective treatment for occlusive or ruptured coronary artery atherosclerotic 
plaques; surgery most often involves harvesting and grafting of healthy, autologous saphe-
nous vein to bypass the occluded artery and facilitate revascularisation of the cardiac tis-
sue [71, 72]. Arteriovenous grafts are however predisposed to reblocking (restenosis), and 
despite extensive research, 10–15% of CABG patients suffer early vein graft failure within 
the first year after surgery, and as many as 50% suffer graft failure within 10 years [71–73]. 
Thrombosis, intimal thickening, and accelerated atherosclerosis are the underlying causes of 
saphenous vein graft failure. Intimal thickening, which serves as a foundation for superim-
posed atherosclerosis, is often the cause of late vein graft failure (Figure 3), while thrombosis 
is the cause of early graft failure. Intimal thickening is a product of aberrant VSMC migration 
into the intima where they proliferate and deposit extracellular matrix.
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6.2. PRH is up-regulated in neointimal cells
PRH expression is up-regulated in the intimal compartment of rat thoracic aortas injured with 
a balloon embolectomy catheter – a robust model for neointimal hyperplasia [37]. However, 
PRH mRNA and protein expression is absent in healthy aorta. Moreover PRH activates tran-
scription of SMemb/NMHC-B, a marker of dedifferentiated VSMCs with a synthetic, prolif-
erative phenotype, and not of differentiated VSMCs with a quiescent, contractile phenotype 
[37]. Together these findings could indicate that PRH promotes VSMC de-differentiation 
and accumulation in the intima, thereby accelerating disease progression. However, ectopic 
overexpression of wild-type PRH in primary cultures of rat aortic VSMCs inhibits cell cycle 
progression, whereas siRNA-mediated knockdown of PRH promotes cell proliferation [38]. 
These data clearly indicate an anti-proliferative role for PRH in VSMCs. Transfection of iso-
lated rat aortic VSMCs with a vector expressing PRH F32E, a mutant that does not bind TLE, 
did not block cell proliferation suggesting that in these cells, PRH inhibits cell cycle pro-
gression in a TLE-independent manner (KSW unpublished observations). Interestingly, PRH 
S163C,S177C exhibited a prolonged anti-mitotic effect with respect to wild-type PRH [38]. 
This indicates that phosphorylation of PRH at Ser163 and Ser177 prevents PRH from inhibit-
ing VSMC proliferation. Moreover, adenovirus-mediated gene transfer of PRH S163C,S177C 
retarded intimal thickening in an ex vivo human saphenous vein organ culture model [38]. 
It is hence likely that PRH is up-regulated during neointima formation in dedifferentiated, 
proliferating VSMCs as a negative feedback mechanism to prevent further rounds of mitosis.
6.3. CK2 activity during intimal thickening
Multiple studies have implicated the involvement of CK2 in the regulation of VSMC prolifer-
ation and pathophysiological intimal thickening. For example, treatment of cultured human 
aortic smooth muscle cells with emodin (1,3,8-trihydroxy-6-methylanthraquinone) – a natu-
rally occurring CK2 inhibitor used in traditional Chinese medicine – blocked platelet-derived 
growth factor (PDGF)- and tumour necrosis factor α (TNF-α)-induced cell proliferation in a 
dose-dependent manner [74]. Also, in the rat aortic VSMC line A10, inhibition of CK2 with the 
synthetic compounds DDZ (daidzein) and DRB (5,6-dichlorobenzimidazole riboside) antag-
onised lysophosphatidic acid-induced cell division [75]. However, emodin, DDZ and DRB 
Figure 3. Intimal hyperplasia in saphenous vein grafts. Intimal hyperplasia in saphenous vein grafts is a consequence of 
the migration of medial VSMCs to the intima and their subsequent proliferation and deposition of extracellular matrix. 
Neointima formation results in narrowing of the lumen and a consequent restriction of blood flow.
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Figure 4. The inhibition of CK2 prevents intimal thickening. Top – phosphorylation of PRH by CK2 prevents PRH from 
inhibiting VSMC proliferation and this contributes to vein graft failure. Bottom – pharmacological inhibition of CK2 
allows PRH to suppress VSMC proliferation and thereby prevent neointima formation. Other CK2 target proteins are 
also likely to play a role in the prevention of intimal thickening following CK2 inhibition.
show high promiscuity as inhibitors [76]. PDGF, basic fibroblast growth factor (bFGF), and 
Wnt proteins are well-recognised atherogenic mitogens that are up-regulated in atheroscle-
rotic and restenotic lesions ([38] and references therein). Interestingly, pharmacological inhibi-
tion of CK2 with the highly selective compounds TBB and K66 suppresses PDGF-, bFGF- and 
Wnt-4-induced cell replication in primary cultures of rat aortic VSMCs [38]. Silencing of CK2 
using exogenous siRNAs also inhibited VSMC proliferation further suggesting that CK2 pro-
motes the proliferation of these cells. Furthermore, treatment of human saphenous vein organ 
cultures with the CK2 inhibitor K66 disrupted neointima formation [38].
6.4. CK2 acts via PRH to modulate VSMC proliferation
One mechanism through which CK2 may facilitate VSMC proliferation could be via blocking 
PRH activity. Treatment with the K66 failed to arrest PDGF- and bFGF-stimulated cell cycle 
progression in VSMCs with depleted levels of PRH [38]. Thus CK2-dependent mitogenic sig-
nal transduction at least in part requires the presence of PRH (Figure 4). Similarly, treatment 
of human immortalised myelogenous K562 cells with the CK2 inhibitor DMAT inhibits cell 
proliferation but has no significant effect on the proliferation of K562 cells in which PRH has 
been knocked down using shRNA [58]. In K562 cells PRH controls cell proliferation via the 
inhibition of VEGF signalling [24, 58]. Further work is required to determine whether PRH 
controls VSMC proliferation via the inhibition of VEGF signalling or whether other signal-
ling pathways targeted by PRH are important in this context. For instance, another poten-
tial mechanism by which PRH might control VSMC proliferation involves urokinase-type 
plasminogen activator (uPA)-mediated signalling [77]. uPA is a serine protease that is up-
regulated in atheromas and restenotic lesions of human arteries [77–79]. In uPA deficient 
mice, subsequent to either electrical or mechanical arterial injury, intimal thickening and cell 
accumulation is significantly reduced compared to wild-type mice [80]. In human umbilical 
vein VSMCs, endogenous uPA has been shown to be involved in the induction of a mito-
genic response by either PDGF or bFGF [77]. Furthermore, in PDGF- or bFGF-stimulated 
cells, pharmacological inhibition of uPA and CK2 with p-aminobenzamidine and 4 μM TBB, 
respectively, markedly enhances the anti-proliferative effects of 4 μM TBB alone in an addi-
tive manner [77]. Intracellular uPA has recently been shown to bind to PRH in endothelial 
Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects246
cells and to prevent PRH from repressing VEGF signalling genes [50]. Therefore it is possible 
that the effects of uPA inhibition on endothelial proliferation and CK2 inhibition on VSMC 
proliferation during intimal thickening are both mediated by PRH.
6.5. Implications for saphenous vein grafts
As protein kinase CK2 is ubiquitously expressed, systemic delivery of a CK2 inhibitor for the 
treatment of saphenous vein graft degeneration may cause unwanted side effects. However, 
perivascular drug delivery systems could be employed for localised, sustained release of a CK2 
inhibitor to a grafted vein. Such a system has been used to deliver sunitinib in a biocompatible 
hyaluronic acid-based hydrogel within a polyactide-co-glycolide perivascular wrap [81]. Other 
approaches for delivery include drug-eluting nanoparticles and drug-linked  antibodies [82].
Gene therapy also has therapeutic potential in alleviating saphenous vein graft stenosis, and 
could be used for the introduction of PRH, particularly PRH S163C,S177C, to grafted vein. 
Genetic manipulation of a venous graft must however occur peri-operatively, meaning there is 
only a single opportunity to complete gene transfer. Therefore, helper-dependent adenovirus 
technology may be necessary to provide prolonged expression of PRH or PRH S163C,S177C 
within the grafted conduit [83, 84]. In a similar instance, delivery of tissue inhibitor of metal-
loproteinase 3 (TIMP-3) has been shown to block neointima formation in autologous porcine 
arteriovenous interposition grafts for up to 3 months [85].
7. Conclusion
The regulation of cell proliferation and cell migration/invasion by PRH is not limited to a 
particular cell type. Similarly, the control of PRH by CK2-dependent phosphorylation is also 
seen in multiple cell types. The PRH-CK2 axis is likely to be important for the regulation of 
cell proliferation and cell behaviour across a broad spectrum of cell types and in a variety of 
disease states. Further work in this area is therefore likely to be of great clinical relevance.
Acknowledgements
We are grateful to the British Heart Foundation (FS/10/58/28515) and the Medical Research 
Council for supporting this work. We apologise to the many authors whose papers we have 
not cited here due to space constraints.
Abbreviations
ATP adenosine triphosphate
bFGF basic fibroblast growth factor
CABG coronary artery bypass graft
Phosphorylation of PRH/HHEX by Protein Kinase CK2 Regulates Cell Proliferation and Cell…
http://dx.doi.org/10.5772/intechopen.72902
247
CK2 protein kinase CK2 (Casein Kinase II)
DDZ daidzein
DMAT 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole)
DRB 5,6-dichlorobenzimidazole riboside
K66 1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole
PDGF platelet-derived growth factor
SDS sodium dodecyl sulphate
SELDI-TOF-MS  surface-enhancer laser desorption/ionisation time-of-flight mass 
spectrophotometry
TBB 4,5,6,7-tetrabromo-1H-benzotriazole
VSMC vascular smooth muscle cell
Author details
Padma-Sheela Jayaraman1, Kerry S. Wadey2, Sarah J. George2 and Kevin Gaston3*
*Address all correspondence to: kevin.gaston@bristol.ac.uk
1 Institute of Cancer and Genome Biology, College of Medical and Dental Sciences, 
University of Birmingham, Birmingham, UK
2 Bristol Medical School, University of Bristol, Bristol Royal Infirmary, Bristol, UK
3 School of Biochemistry, University of Bristol, Bristol, UK
References
[1] Soufi A, Jayaraman PS. PRH/Hex: An oligomeric transcription factor and multifunc-
tional regulator of cell fate. Biochemical Journal. 2008;412(3):399-413
[2] Crompton MR, Bartlett TJ, MacGregor AD, Manfioletti G, Buratti E, Giancotti V, Goodwin 
GH. Identification of a novel vertebrate homeobox gene expressed in haematopoietic 
cells. Nucleic Acids Research. 1992;20(21):5661-5667
[3] Hromas R, Radich J, Collins S. PCR cloning of an orphan homeobox gene (PRH) prefer-
entially expressed in myeloid and liver cells 30. Biochemical and Biophysical Research 
Communications. 1993;195(2):976-983
[4] Bedford FK, Ashworth A, Enver T, Wiedemann LM. HEX: A novel homeobox gene 
expressed during haematopoiesis and conserved between mouse and human. Nucleic 
Acids Research. 1993;21(5):1245-1249
Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects248
[5] Hallaq H, Pinter E, Enciso J, McGrath J, Zeiss C, Brueckner M, Madri J, Jacobs HC, 
Wilson CM, Vasavada H, et al. A null mutation of Hhex results in abnormal cardiac 
development, defective vasculogenesis and elevated Vegfa levels. Development. 2004; 
131(20):5197-5209
[6] Martinez Barbera JP, Clements M, Thomas P, Rodriguez T, Meloy D, Kioussis D, 
Beddington RS. The homeobox gene Hex is required in definitive endodermal tissues 
for normal forebrain, liver and thyroid formation. Development. 2000;127(11):2433-2445
[7] Keng VW, Yagi H, Ikawa M, Nagano T, Myint Z, Yamada K, Tanaka T, Sato A, Muramatsu I, 
Okabe M, et al. Homeobox gene Hex is essential for onset of mouse embryonic liver 
development and differentiation of the monocyte lineage. Biochemical and Biophysical 
Research Communications. 2000;276(3):1155-1161
[8] Brickman JM, Jones CM, Clements M, Smith JC, Beddington RS. Hex is a transcriptional 
repressor that contributes to anterior identity and suppresses Spemann organiser func-
tion. Development. 2000;127(11):2303-2315
[9] Manfioletti G, Gattei V, Buratti E, Rustighi A, De IA, Aldinucci D, Goodwin GH, Pinto A. 
Differential expression of a novel proline-rich homeobox gene (Prh) in human hemato-
lymphopoietic cells. Blood. 1995;85(5):1237-1245
[10] Guiral M, Bess K, Goodwin G, Jayaraman PS. PRH represses transcription in hematopoi-
etic cells by at least two independent mechanisms. The Journal of Biological Chemistry. 
2001;276(4):2961-2970
[11] Desjobert C, Noy P, Swingler T, Williams H, Gaston K, Jayaraman PS. The PRH/Hex 
repressor protein causes nuclear retention of Groucho/TLE co-repressors. Biochemical 
Journal. 2009;417(1):121-132
[12] Schaefer LK, Shuguang W, Schaefer TS. Functional interaction of Jun and homeodomain 
proteins. The Journal of Biological Chemistry. 2001;276:43074-43082
[13] Tanaka T, Inazu T, Yamada K, Myint Z, Keng VW, Inoue Y, Taniguchi N, Noguchi T. 
cDNA cloning and expression of rat homeobox gene, Hex, and functional characteriza-
tion of the protein. Biochemical Journal. 1999;339(1):111-117
[14] Topcu Z, Mack DL, Hromas RA, Borden KL. The promyelocytic leukemia protein PML 
interacts with the proline-rich homeodomain protein PRH: A RING may link hemato-
poiesis and growth control. Oncogene. 1999;18(50):7091-7100
[15] Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. The proline-rich 
homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 
mRNA transport and growth. The EMBO Journal. 2003;22(3):689-703
[16] Bess KL, Swingler TE, Rivett AJ, Gaston K, Jayaraman PS. The transcriptional repressor 
protein PRH interacts with the proteasome. Biochemical Journal. 2003;374(3):667-675
[17] Soufi A, Noy P, Buckle M, Sawasdichai A, Gaston K, Jayaraman PS. CK2 phosphoryla-
tion of the PRH/Hex homeodomain functions as a reversible switch for DNA binding. 
Nucleic Acids Research. 2009;37:3288-3300
Phosphorylation of PRH/HHEX by Protein Kinase CK2 Regulates Cell Proliferation and Cell…
http://dx.doi.org/10.5772/intechopen.72902
249
[18] Kasamatsu S, Sato A, Yamamoto T, Keng VW, Yoshida H, Yamazaki Y, Shimoda M, 
Miyazaki J, Noguchi T. Identification of the transactivating region of the homeodomain 
protein, hex. Journal of Biochemistry (Tokyo). 2004;135(2):217-223
[19] Denson LA, Karpen SJ, Bogue CW, Jacobs HC. Divergent homeobox gene hex regu-
lates promoter of the Na(+)-dependent bile acid cotransporter 5. American Journal of 
Physiology-Gastrointestinal and Liver Physiology. 2000;279(2):G347-G355
[20] Soufi A, Smith C, Clarke AR, Gaston K, Jayaraman PS. Oligomerisation of the develop-
mental regulator proline rich homeodomain (PRH/Hex) is mediated by a novel proline-
rich dimerisation domain. Journal of Molecular Biology. 2006;358(4):943-962
[21] Williams H, Jayaraman PS, Gaston K. DNA wrapping and distortion by an oligomeric 
homeodomain protein. Journal of Molecular Biology. 2008;383(1):10-23
[22] Cong R, Jiang X, Wilson CM, Hunter MP, Vasavada H, Bogue CW. Hhex is a direct 
repressor of endothelial cell-specific molecule 1 (ESM-1). Biochemical and Biophysical 
Research Communications. 2006;346(2):535-545
[23] Zamparini AL, Watts T, Gardner CE, Tomlinson SR, Johnston GI, Brickman JM. Hex 
acts with beta-catenin to regulate anteroposterior patterning via a Groucho-related co-
repressor and nodal. Development. 2006;133(18):3709-3722
[24] Noy P, Williams H, Sawasdichai A, Gaston K, Jayaraman P-S. PRH/Hhex controls cell 
survival through coordinate transcriptional regulation of vascular endothelial growth 
factor signaling. Molecular and Cellular Biology. 2010;30(9):2120-2134
[25] Swingler TE, Bess KL, Yao J, Stifani S, Jayaraman PS. The proline-rich homeodomain 
protein recruits members of the Groucho/Transducin-like enhancer of split protein fam-
ily to co-repress transcription in hematopoietic cells. Journal of Biological Chemistry. 
2004;279(33):34938-34947
[26] Shields BJ, Jackson JT, Metcalf D, Shi W, Huang Q, Garnham AL, Glaser SP, Beck D, 
Pimanda JE, Bogue CW, et al. Acute myeloid leukemia requires Hhex to enable PRC2-
mediated epigenetic repression of Cdkn2a. Genes & Development. 2016;30(1):78-91
[27] Minami T, Murakami T, Horiuchi K, Miura M, Noguchi T, Miyazaki J, Hamakubo T, 
Aird WC, Kodama T. Interaction between hex and GATA transcription factors in vas-
cular endothelial cells inhibits flk-1/KDR-mediated vascular endothelial growth factor 
signaling. Journal of Biological Chemistry. 2004;279(20):20626-20635
[28] Marfil V, Blazquez M, Serrano F, Castell JV, Bort R. Growth-promoting and tumouri-
genic activity of c-Myc is suppressed by Hhex. Oncogene. 2014;34(23):3011-3022
[29] Oyama Y, Kawai-Kowase K, Sekiguchi K, Sato M, Sato H, Yamazaki M, Ohyama Y, 
Aihara Y, Iso T, Okamaoto E, et al. Homeobox protein Hex facilitates serum respon-
sive factor-mediated activation of the SM22alpha gene transcription in embryonic fibro-
blasts. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24(9):1602-1607
Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects250
[30] Tanaka H, Yamamoto T, Ban T, Satoh S, Tanaka T, Shimoda M, Miyazaki J, Noguchi T. 
Hex stimulates the hepatocyte nuclear factor 1alpha-mediated activation of transcrip-
tion. Archives of Biochemistry and Biophysics. 2005;442(1):117-124
[31] Jankovic D, Gorello P, Liu T, Ehret S, La SR, Desjobert C, Baty F, Brutsche M, Jayaraman PS, 
Santoro A, et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in 
acute myeloid leukemia. Blood. 2008;111(12):5672-5682
[32] Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, 
Borden KL. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA 
transport impedes hematopoietic differentiation and contributes to leukemogenesis. 
Molecular and Cellular Biology. 2003;23(24):8992-9002
[33] D'Elia AV, Tell G, Russo D, Arturi F, Puglisi F, Manfioletti G, Gattei V, Mack DL, Cataldi P, 
Filetti S, et al. Expression and localization of the homeodomain-containing protein 
HEX in human thyroid tumors. The Journal of Clinical Endocrinology and Metabolism. 
2002;87(3):1376-1383
[34] Puppin C, Puglisi F, Pellizzari L, Manfioletti G, Pestrin M, Pandolfi M, Piga A, Di LC, 
Damante G. HEX expression and localization in normal mammary gland and breast 
carcinoma. BMC Cancer. 2006;6:e192
[35] Siddiqui YH, Kershaw RM, Humphreys EH, Assis Junior EM, Chaudhri S, Jayaraman PS, 
Gaston K. CK2 abrogates the inhibitory effects of PRH/HHEX on prostate cancer cell 
migration and invasion and acts through PRH to control cell proliferation. Oncogene. 
2017;6(1):e293
[36] Kershaw RM, Roberts D, Wragg J, Shaaban AM, Humphreys E, Halsall J, Price L, 
Bicknell R, Gaston K, Jayaraman PS. Proline-rich homeodomain protein (PRH/HHEX) is 
a suppressor of breast tumour growth. Oncogene. 2017;6(6):e346
[37] Sekiguchi K, Kurabayashi M, Oyama Y, Aihara Y, Tanaka T, Sakamoto H, Hoshino Y, 
Kanda T, Yokoyama T, Shimomura Y, et al. Homeobox protein hex induces SMemb/non-
muscle myosin heavy chain-B gene expression through the cAMP-responsive element. 
Circulation Research. 2001;88(1):52-58
[38] Wadey KS, Brown BA, Sala-Newby GB, Jayaraman PS, Gaston K, George SJ. Protein 
kinase CK2 inhibition suppresses neointima formation via a proline-rich homeodomain-
dependent mechanism. Vascular Pharmacology. 2017;99:34-44
[39] Su J, You P, Zhao JP, Zhang SL, Song SH, ZR F, Ye LW, Zi XY, Xie DF, Zhu MH, et al. 
A potential role for the homeoprotein Hhex in hepatocellular carcinoma progression. 
Medical Oncology. 2012;29(2):1059-1067
[40] Gaston K, Tsitsilianos MA, Wadey K, Jayaraman PS. Misregulation of the proline rich 
homeodomain (PRH/HHEX) protein in cancer cells and its consequences for tumour 
growth and invasion. Cell & Bioscience. 2016;6:e12
Phosphorylation of PRH/HHEX by Protein Kinase CK2 Regulates Cell Proliferation and Cell…
http://dx.doi.org/10.5772/intechopen.72902
251
[41] Hansen GM, Justice MJ. Activation of Hex and mEg5 by retroviral insertion may contrib-
ute to mouse B-cell leukemia. Oncogene. 1999;18(47):6531-6539
[42] Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, Nakamura T, Shaughnessy JD Jr, 
Jenkins NA, Copeland NG. Leukaemia disease genes: Large-scale cloning and pathway 
predictions. Nature Genetics. 1999;23(3):348-353
[43] Mack DL, Leibowitz DS, Cooper S, Ramsey H, Broxmeyer HE, Hromas R. Down-
regulation of the myeloid homeobox protein Hex is essential for normal T-cell develop-
ment. Immunology. 2002;107(4):444-451
[44] George A, Morse HC III, Justice MJ. The homeobox gene Hex induces T-cell-derived lym-
phomas when overexpressed in hematopoietic precursor cells. Oncogene. 2003;22(43): 
6764-6773
[45] McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, Rabbitts TH, 
Jane SM, Curtis DJ. The Lmo2 oncogene initiates leukemia in mice by inducing thymo-
cyte self-renewal. Science. 2010;327(5967):879-883
[46] Smith S, Tripathi R, Goodings C, Cleveland S, Mathias E, Hardaway JA, Elliott N, Yi Y, 
Chen X, Downing J, et al. LIM domain only-2 (LMO2) induces T-cell leukemia by two 
distinct pathways. PLoS One. 2014;9(1):e85883
[47] Kubo A, Chen V, Kennedy M, Zahradka E, Daley GQ, Keller G. The homeobox gene 
HEX regulates proliferation and differentiation of hemangioblasts and endothelial cells 
during ES cell differentiation. Blood. 2005;105(12):4590-4597
[48] Noy P, Sawasdichai A, Jayaraman PS, Gaston K. Protein kinase CK2 inactivates PRH/
Hhex using multiple mechanisms to de-repress VEGF-signalling genes and promote cell 
survival. Nucleic Acids Research. 2012;40(18):9008-9020
[49] Nakagawa T, Abe M, Yamazaki T, Miyashita H, Niwa H, Kokubun S, Sato Y. HEX acts 
as a negative regulator of angiogenesis by modulating the expression of angiogenesis-
related gene in endothelial cells in vitro. Arteriosclerosis, Thrombosis, and Vascular 
Biology. 2003;23(2):231-237
[50] Stepanova V, Jayaraman PS, Zaitsev SV, Lebedeva T, Bdeir K, Kershaw R, Holman KR, 
Parfyonova YV, Semina EV, Beloglazova IB, et al. Urokinase-type plasminogen activator 
(uPA) promotes angiogenesis by attenuating proline-rich homeodomain protein (PRH) 
transcription factor activity and de-repressing vascular endothelial growth factor (VEGF) 
receptor expression. The Journal of Biological Chemistry. 2016;291(29):15029-15045
[51] Li L, Liu M, Kang L, Li Y, Dai Z, Wang B, Liu S, Chen L, Tan Y, Wu G. HHEX: A cross-
talker between HCMV infection and proliferation of VSMCs. Frontiers in Cellular and 
Infection Microbiology. 2016;6:e169
[52] Litchfield DW. Protein kinase CK2: Structure, regulation and role in cellular decisions of 
life and death. Biochemical Journal. 2003;369(1):1-15
Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects252
[53] Wirkner U, Voss H, Lichter P, Ansorge W, Pyerin W. The human gene (CSNK2A1) cod-
ing for the casein kinase II subunit alpha is located on chromosome 20 and contains 
tandemly arranged Alu repeats. Genomics. 1994;19(2):257-265
[54] Bodenbach L, Fauss J, Robitzki A, Krehan A, Lorenz P, Lozeman FJ, Pyerin W. Recombinant 
human casein kinase II. A study with the complete set of subunits (alpha, alpha' and 
beta), site-directed autophosphorylation mutants and a bicistronically expressed holo-
enzyme. European Journal of Biochemistry. 1994;220(1):263-273
[55] Yang-Feng TL, Naiman T, Kopatz I, Eli D, Dafni N, Canaani D. Assignment of the 
human casein kinase II alpha' subunit gene (CSNK2A1) to chromosome 16p13.2-p13.3. 
Genomics. 1994;19(1):173
[56] Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor alpha-
induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. The 
Journal of Biological Chemistry. 2000;275(42):32592-32597
[57] Stepanova V, Jerke U, Sagach V, Lindschau C, Dietz R, Haller H, Dumler I. Urokinase-
dependent human vascular smooth muscle cell adhesion requires selective vitronec-
tin phosphorylation by ectoprotein kinase CK2. The Journal of Biological Chemistry. 
2002;277(12):10265-10272
[58] Noy P, Gaston K, Jayaraman PS. Dasatinib inhibits leukaemic cell survival by decreasing 
PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes. 
Leukemia Research. 2012;36(11):1434-1437
[59] Donella-Deana A, Cesaro L, Sarno S, Ruzzene M, Brunati AM, Marin O, Vilk G, Doherty-
Kirby A, Lajoie G, Litchfield DW, et al. Tyrosine phosphorylation of protein kinase CK2 
by Src-related tyrosine kinases correlates with increased catalytic activity. Biochemical 
Journal. 2003;372(3):841-849
[60] Mishra S, Reichert A, Cunnick J, Senadheera D, Hemmeryckx B, Heisterkamp N, Groffen J. 
Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates prolif-
eration of Bcr/Abl-expressing cells. Oncogene. 2003;22(51):8255-8262
[61] Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE, 
Seldin DC. Protein kinase CK2: Signaling and tumorigenesis in the mammary gland. 
Molecular and Cellular Biochemistry. 2001;227(1-2):153-165
[62] Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K. Nuclear casein kinase 2 
(CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate. 
1994;24(1):11-16
[63] Daya-Makin M, Sanghera JS, Mogentale TL, Lipp M, Parchomchuk J, Hogg JC, Pelech SL. 
Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in 
human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Research. 
1994;54(8):2262-2268
Phosphorylation of PRH/HHEX by Protein Kinase CK2 Regulates Cell Proliferation and Cell…
http://dx.doi.org/10.5772/intechopen.72902
253
[64] Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K. Elevated protein kinase 
CK2 activity in chromatin of head and neck tumors: Association with malignant trans-
formation. Cancer Letters. 1996;101(1):31-35
[65] Stalter G, Siemer S, Becht E, Ziegler M, Remberger K, Issinger OG. Asymmetric expression 
of protein kinase CK2 subunits in human kidney tumors. Biochemical and Biophysical 
Research Communications. 1994;202(1):141-147
[66] Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, Teruya-
Feldstein J, Tempst P, Pandolfi PP. A CK2-dependent mechanism for degradation of the 
PML tumor suppressor. Cell. 2006;126(2):269-283
[67] Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA, Ruzzene M. 
Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death and Differ-
entiation. 2005;12(6):668-677
[68] Battistutta R, Cozza G, Pierre F, Papinutto E, Lolli G, Sarno S, O'Brien SE, Siddiqui-Jain A, 
Haddach M, Anderes K, et al. Unprecedented selectivity and structural determinants of 
a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. 
Biochemistry. 2011;50(39):8478-8488
[69] Martins LR, Lucio P, Melao A, Antunes I, Cardoso BA, Stansfield R, Bertilaccio MT, Ghia P, 
Drygin D, Silva MG, et al. Activity of the clinical-stage CK2-specific inhibitor CX-4945 
against chronic lymphocytic leukemia. Leukemia. 2014;28(1):179-182
[70] Steinberg M. Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelog-
enous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. 
Clinical Therapeutics. 2007;29(11):2289-2308
[71] Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, 
Passamani E, Norris R, et al. Effect of coronary artery bypass graft surgery on survival: 
Overview of 10-year results from randomised trials by the coronary artery bypass graft 
surgery trialists collaboration. Lancet. 1994;344(8922):563-570
[72] Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, 
Herrmann HC, Hillis LD, Hutter AM Jr, et al. ACC/AHA 2004 guideline update for coro-
nary artery bypass graft surgery: A report of the American College of Cardiology/American 
Heart Association task force on practice guidelines (committee to update the 1999 guide-
lines for coronary artery bypass graft surgery). Circulation. 2004;110(14):e340-e437
[73] Harskamp RE, Lopes RD, Baisden CE, de Winter RJ, Alexander JH. Saphenous vein graft 
failure after coronary artery bypass surgery: Pathophysiology, management, and future 
directions. Annals of Surgery. 2013;257(5):824-833
[74] Heo SK, Yun HJ, Park WH, Park SD. Emodin inhibits TNF-alpha-induced human aortic 
smooth-muscle cell proliferation via caspase- and mitochondrial-dependent apoptosis. 
Journal of Cellular Biochemistry. 2008;105(1):70-80
Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects254
[75] YJ X, Rathi SS, Chapman DC, Arneja AS, Dhalla NS. Mechanisms of lysophosphatidic 
acid-induced DNA synthesis in vascular smooth muscle cells. Journal of Cardiovascular 
Pharmacology. 2003;41(3):381-387
[76] Pagano MA, Bain J, Kazimierczuk Z, Sarno S, Ruzzene M, Di Maira G, Elliott M, 
Orzeszko A, Cozza G, Meggio F, et al. The selectivity of inhibitors of protein kinase CK2: 
An update. The Biochemical Journal. 2008;415(3):353-365
[77] Padro T, Mesters RM, Dankbar B, Hintelmann H, Bieker R, Kiehl M, Berdel WE, Kienast J. 
The catalytic domain of endogenous urokinase-type plasminogen activator is required 
for the mitogenic activity of platelet-derived and basic fibroblast growth factors in 
human vascular smooth muscle cells. Journal of Cell Science. 2002;115(9):1961-1971
[78] Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen acti-
vator expression in human atherosclerotic lesions. Arteriosclerosis, Thrombosis, and 
Vascular Biology. 1995;15(9):1444-1455
[79] Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plas-
minogen activator system in human coronary atherosclerosis. Arteriosclerosis, Throm-
bosis, and Vascular Biology. 1995;15(9):1432-1443
[80] Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase 
but not tissue plasminogen activator mediates arterial neointima formation in mice. 
Circulation Research. 1997;81(5):829-839
[81] Sanders WG, Hogrebe PC, Grainger DW, Cheung AK, Terry CM. A biodegradable peri-
vascular wrap for controlled, local and directed drug delivery. Journal of Controlled 
Release: Official Journal of the Controlled Release Society. 2012;161(1):81-89
[82] Thomas AC. Targeted treatments for restenosis and vein graft disease. ISRN Vascular 
Medicine. 2012;2012:23
[83] Oka K, Pastore L, Kim IH, Merched A, Nomura S, Lee HJ, Merched-Sauvage M, Arden-
Riley C, Lee B, Finegold M, et al. Long-term stable correction of low-density lipoprotein 
receptor-deficient mice with a helper-dependent adenoviral vector expressing the very 
low-density lipoprotein receptor. Circulation. 2001;103(9):1274-1281
[84] Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L, Beaudet A, Chan L. Long-
term stable expression of human apolipoprotein A-I mediated by helper-dependent 
adenovirus gene transfer inhibits atherosclerosis progression and remodels atheroscle-
rotic plaques in a mouse model of familial hypercholesterolemia. Circulation. 2003;107(21): 
2726-2732
[85] George SJ, Wan S, Hu J, MacDonald R, Johnson JL, Baker AH. Sustained reduction of 
vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation. 2011; 
124(11 Suppl):S135-S142
Phosphorylation of PRH/HHEX by Protein Kinase CK2 Regulates Cell Proliferation and Cell…
http://dx.doi.org/10.5772/intechopen.72902
255

